Why M&A strategy focusing on selling low-margin business inhibits innovation, lowers entry barriers, dilutes expertise, and weakens patient ties — In the last years, Mergers and Acquisitions strategies in life science have reflected the desire of large organizations to adapt to changing market conditions and to focus on areas with a higher potential for size and profit growth. To increase shareholder value, pharmaceutical companies have expanded into precision medicine, oncology…

It is time to reconsider how we think about sustainability and incorporate it into all aspects of our consumption, manufacturing, innovation, and design. — The concern for “future generations” is at the heart of many cultures that have historically practiced environmental conservation and resource preservation. Hans Carl von Carlowitz (1645–1714) was the first to discuss sustainability in 1713. …

Key principles and suggestions to foster collaboration and unleash the potential of repurposing drugs, for more equal and accessible healthcare. — We can’t learn, be active citizens, get a job, or be a part of a group unless we have good health. This means that every country needs to make research and availability of drugs a top priority. That has been exacerbated by the current pandemic. Life Science research has always…

Becoming Digital has less to do with implementing technologies than what we tend to think. — In markets protected by technology challenges, government regulations, patents, start-up costs, or education and licensing requirements, organizations have kept the same business model for decades, using technologies merely to cut costs and protect margins. In fact, before the pandemic, only born-digital companies, owning the approach and competencies to prosper in…

Chart a new course in business strategy: Harness the prowess of air traffic control to pilot enterprises toward unmatched success with Supply Planning Control Towers — Navigating the vast, complex business landscape resembles piloting an aircraft through an ever-changing, dynamic sky. Each decision, each transformation, and each strategy is a unique aircraft requiring expert guidance and precise navigation. …

Navigate the critical balance of M&A, affordability, and alternative funding pathways shaping our global healthcare’s future — Imagine a global chess match, where each move determines the trajectory of our healthcare system. On the chessboard are large pharmaceutical organizations, considered the vanguards of medical innovation, and the Federal Trade Commission (FTC). Their moves shape the intricate dynamics of the industry.

Discover the human capital’s role, the strategic interventions sequence, and the right partnership’s importance in achieving digital success in life sciences — Imagine a doctor examining a patient. The stethoscope glides, the thermometer clicks, and the blood pressure cuff inflates. Every symptom is noted, every sign investigated. Only then, with a clear understanding of the patient’s health status, can the physician chart the path to recovery.

Uncover the 2023 life science transformation towards an integrated supply chain, its potential, and challenges — Pharmaceuticals are on the cusp of a revolution. The year 2023 marks a pivotal point, with the industry moving towards an integrated supply chain ecosystem. This system enhances collaboration from API suppliers to end users and promises to radically alter the landscape, bolstering efficiency, affordability, and drug availability.

Revolutionizing Supply Chain Efficiency: Unleashing the Power of Demand Planning, Technology, and Clinical Trials in the Pharmaceutical Industry — The high-stakes world of pharmaceuticals isn’t solely defined by groundbreaking lab discoveries and innovative therapies. Successfully delivering life-saving drugs to patients also hinges on effectively navigating intricate supply chains, overcoming regulatory hurdles, and adapting to evolving business models. For pharmaceutical companies, demand planning is instrumental in capitalizing on generic efficiencies…